Announcement on Subsidiary Receiving Approval for Chemical API Listing Application

Saito Biotech Co., Ltd.·July 22, 2026·2 pages

✨ AI Summary

Shandong Sairui Biotechnology Co., Ltd. announces its subsidiary, Shandong Sirui Pharmaceutical Co., Ltd., has received approval from the NMPA for its Fluticasone Furoate API listing application. This approval expands the company's product line and enhances market competitiveness. However, sales are not yet initiated, and market performance faces uncertainties due to regulatory compliance and market dynamics.

Summary generated by AI · Always verify with source document

Full Translation

AI Translation· gemini_document

Securities Code: 300583 Securities Abbreviation: Sairui Bio Announcement No.: 2026-042

Shandong Sairui Biotechnology Co., Ltd.

Announcement on Subsidiary Receiving Approval for Chemical API Listing Application

The Company and all members of the Board of Directors guarantee that the information disclosed is true, accurate, and complete, and that there are no false records, misleading statements, or major omissions.

Shandong Sairui Biotechnology Co., Ltd. (hereinafter referred to as the "Company") announced that its holding subsidiary, Shandong Sirui Pharmaceutical Co., Ltd., recently received the "Chemical API Listing Application Approval Notice" issued by the National Medical Products Administration for Fluticasone Furoate. The relevant situation is hereby announced as follows:

I. API Registration Information

Chemical API Name: Fluticasone Furoate

Registration Number: Y20250000018

Packaging Specific

Free accounts get 10 full releases per month. Pro subscribers get unlimited access.